Gothenburg, Sweden

Lars A Hanson

This inventor holds 2 USPTO granted patents. Top assignee: Pharmasurgics in Sweden Ab. Active years: 2007-2010.


% Patents Active = 50.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 8(Granted Patents)


Company Filing History:


Years Active: 2007-2010

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Lars A. Hanson: Innovator in Peptide Research

Introduction

Lars A. Hanson is a notable inventor based in Göteborg, Sweden. He has made significant contributions to the field of peptide research, particularly in the development of medicinal products. With a total of 2 patents, his work focuses on innovative solutions for health-related issues.

Latest Patents

Hanson's latest patents include groundbreaking inventions related to peptides based on the sequence of human lactoferrin. These peptides consist of at least seven subsequent amino acids from positions 12-40 in the human lactoferrin sequence. The inventions aim to create medicinal products that are effective in treating and preventing infections, inflammations, and tumors. Additionally, these peptides are intended for use in food products, such as infant formula, enhancing their nutritional value.

Career Highlights

Lars A. Hanson is associated with Pharmasurgics in Sweden AB, where he continues to advance his research and development efforts. His work has garnered attention for its potential impact on health and nutrition.

Collaborations

Hanson collaborates with esteemed colleagues, including Lars Baltzer and Inger Mattsby-Baltzer, contributing to a dynamic research environment that fosters innovation.

Conclusion

Lars A. Hanson exemplifies the spirit of innovation in peptide research, with his patents paving the way for advancements in medicinal and nutritional applications. His contributions are poised to make a significant impact in the field of health.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…